cayston 75 mg 84 vials liofil + 88 amp disolv 1ml
saflutan 15 microgramos/ml colirio en solucion en envase unidosis
santen oy - tafluprost - excipientes: glicerol,dihidrogenofosfato de sodio dihidratado,edetato de disodio,polisorbato 80,hidroxido de sodio (e-524) - preparados contra el glaucoma y miÓticos1) - análogos de prostaglandinas - tafluprost
ácido aminocaproico
sgpharma pvt. ltd., mumbai, india. - Ácido aminocaproico - solución para infusión iv - 250 mg/ml
ácido aminocaproico
sgpharma pvt. ltd.. - Ácido aminocaproico - solución para infusión iv - 250 mg/ml
revlimid cápsulas 15 mg (lenalidomida)
bristol - myers squibb de chile - lenalidomida - sin formulas
eritromicina 250 mg /5 ml suspension oral "uso pediatrico"
genfar casa de representaciones, s.a. - eritromicina - suspensi - 250mg/5ml(a1)
revlimid cápsulas 25 mg (lenalidomida)
bristol - myers squibb de chile - lenalidomida - sin formulas
bronchitol
pharmaxis europe limited - manitol - fibrosis quística - preparaciones para la tos y el resfriado - bronchitol está indicado para el tratamiento de la fibrosis quística (fq) en adultos mayores de 18 años como terapia complementaria al mejor estándar de atención.
kalydeco
vertex pharmaceuticals (ireland) limited - ivacaftor - fibrosis quística - otros productos del sistema respiratorio - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 y 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 y 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.
orkambi
vertex pharmaceuticals (ireland) limited - lumacaftor, ivacaftor - fibrosis quística - otros productos del sistema respiratorio - orkambi comprimidos está indicado para el tratamiento de la fibrosis quística (fq) en pacientes mayores de 6 años y más que son homocigotos para la mutación f508del en el gen cftr. orkambi granules are indicated for the treatment of cystic fibrosis (cf) in children aged 1 year and older who are homozygous for the f508del mutation in the cftr gene.